Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin glargine/lixisenatide - Sanofi

Next Previous
Drug Profile

Insulin glargine/lixisenatide - Sanofi

Alternative Names: AVE0010/Lantus®; HOE901/AVE0010; iGlarLixi; Insulin glargine/lixisenatide; Lantus®/lixisenatide single combination product; Lantus®/Lyxumia®; LixiLan; Lixisenatide + Lantus®; Lixisenatide/Lantus®; Lyxumia®/Lantus®; Soliqua; Soliqua®100/33; Suliqua

Latest Information Update: 20 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis; Zealand Pharma
  • Developer Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 20 Jun 2025 Efficacy data from a phase III trial in Type 2 diabetes presented at the 85th Annual Scientific Sessions of the American Diabetes Association (ADA-2025)
  • 09 Dec 2024 No development reported - Phase-III for Type 2 diabetes mellitus (Treatment-experienced) in Czech Republic, Austria, Sweden, Bulgaria, Bulgaria, Greece, China, Spain (SC)
  • 21 Jun 2024 Efficacy and adverse events data from a phase III trial in Type 2 diabetes mellitus released by Sanofi

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top